Business
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting
ROCKVILLE, Md., April 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., April 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that three oral presentations, and several poster presentations, will be presented at the American Society of Gene and Cell Therapy's 23rd Annual Meeting taking place May 12-15, 2020 in virtual format. Presentations and posters will be available at www.asgct.org. \nThe oral presentations include:\nAbstract Title: Quantitative PET/CT based pharmacokinetic study of AAV9 administered to the cerebrospinal fluid of non-human primates (abstract #135) Session Title: AAV Vectors Preclinical and Proof-of-Concept Studies in Optimizing the ToolboxPresenter: Mikhail Papisov, Ph.D., Massachusetts General Hospital, Shriners Hospitals for Children, Harvard Medical SchoolDate/Time: Tuesday, May 12, 2020 from 4:00 - 4:15 p.m. ET\nAbstract Title: RGX-314 Ocular Gene Therapy: Overview of Phase I/IIa Ongoing Trial for Neovascular Age-related Macular Degeneration (nAMD) and Future Directions (abstract #1305)Session Title: AAV Vectors - Clinical StudiesPresenter: Olivier Danos, Ph.D., Senior Vice President and Chief Scientific Officer, REGENXBIO Date/Time: Friday, May 15, 2020 from 10:15-10:30 a.m. ET\nAbstract Title: AAV gene therapy in mucopolysaccharidosis IVA murine models (abstract #1351)Session Title: Gene Therapy for Inborn Errors of Metabolism: New ApproachesPresenter: Shunji Tomatsu, M.D., Ph.D., Nemours/Alfred I. duPont Hospital for ChildrenDate/Time: Friday, May 15, 2020 from 11:15-11:30 a.m. ET\nThe posters include:\nAbstract Title: AAV-mediated antibody delivery for hereditary angioedema (abstract #190)Presenter: Joseph T. Bruder, Ph.D., Senior Director, Target Discovery, REGENXBIOSession Title: AAV Vectors - Preclinical and Proof-of-Concept StudiesDate/Time: Tuesday, May 12, 2020 from 5:30-6:30 p.m. ET\nAbstract Title: Interim data from the first in human RGX-121 gene therapy trial for the treatment of severe MPS II (Hunter syndrome) (abstract #614) Presenter: Marie-Laure Nevoret, M.D., Senior Clinical Development Lead, REGENXBIOSession Title: AAV Vectors - Clinical StudiesDate/Time: Wednesday, May 13, 2020 from 5:30-6:30 p.m. ET\nAbstract Title: Development of a vectorized ant...